Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 6/20 | 0.80 |
| ▸ | DRD2 | P14416 | 3/20 | 0.80 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.65 |
| ▸ | DRD5 | P21918 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | THPO | P40225 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.59 |
| ▸ | GPR183 | P32249 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10744149 | 0.85 | DRD1 (0.81) | DRD1DRD2DRD5CYP1A2CYP2D6 | |
| SCHEMBL4031452 | 0.84 | SLC6A2 (0.72) | DRD1DRD2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4029581 | 0.84 | SLC6A2 (0.72) | DRD1DRD2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11639888 | 0.81 | SLC6A2 (0.72) | DRD1DRD2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4458855 | 0.80 | SLC6A2 (0.62) | DRD1DRD2SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL11640224 | 0.79 | SLC6A2 (0.70) | DRD1DRD2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4469070 | 0.79 | SLC6A2 (0.67) | DRD1DRD2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4032379 | 0.79 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP1A2CYP2D6 | |
| SCHEMBL5246721 | 0.79 | SLC6A2 (1.00) | DRD1DRD2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4031314 | 0.79 | SLC6A2 (1.00) | DRD1DRD2SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911453-B2 | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-28 | — | — | US | claimed |
| EP-1453810-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, THE USE THEREOF AS MEDICAMENTS, IN ADDITION TO A MEDICAMENT CONTAINING SAME | Aventis Pharma Deutschland GmbH (DE) | 2004-09-08 | — | — | EP | claimed |
| US-20040044211-A1 | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-03-04 | — | — | US | claimed |
| WO-2003048129-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, THE USE THEREOF AS MEDICAMENTS, IN ADDITION TO A MEDICAMENT CONTAINING SAME | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-06-12 | — | — | WO | claimed |
| EP-1453810-B1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, THE USE THEREOF AS MEDICAMENTS, IN ADDITION TO A MEDICAMENT CONTAINING SAME | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-03-18 | — | — | EP | disclosed |
| EP-1453810-B1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, THE USE THEREOF AS MEDICAMENTS, IN ADDITION TO A MEDICAMENT CONTAINING SAME | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-03-18 | — | — | EP | disclosed |
| US-6911453-B2 | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-28 | — | — | US | disclosed |
| US-20050009864-A1 | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-13 | — | — | US | disclosed |
| EP-1453810-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, THE USE THEREOF AS MEDICAMENTS, IN ADDITION TO A MEDICAMENT CONTAINING SAME | Aventis Pharma Deutschland GmbH (DE) | 2004-09-08 | — | — | EP | disclosed |
| US-20040044211-A1 | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-03-04 | — | — | US | disclosed |
| WO-2003048129-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, THE USE THEREOF AS MEDICAMENTS, IN ADDITION TO A MEDICAMENT CONTAINING SAME | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009864-A1 | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them | ABCB11, SLC10A1, PON1 | DRD1 2289/4885DRD2 1797/4885SLC6A2 16/4885 |
| US-20040044211-A1 | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them | ABCB11, SLC10A1, PON1 | DRD1 1933/4885DRD2 1590/4885SLC6A2 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.